Cancer Hospital Chinese Academy Of Medical Science, Shenzhen Center
Clinical trials sponsored by Cancer Hospital Chinese Academy Of Medical Science, Shenzhen Center, explained in plain language.
-
Can a Chemo-Immunotherapy cocktail extend life in advanced stomach cancer?
Disease control Not yet recruitingResearchers are testing a combination of three drugs in adults with advanced gastric cancer that has grown after one standard chemotherapy regimen and whose tumors carry the PD-L1 protein. The drugs are irinotecan liposome (a chemotherapy wrapped in fat particles), fruquintinib (…
Phase 2 • Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Promising new combo targets tough head and neck cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted therapy) and pucotenlimab (an immunotherapy)—as a first treatment for advanced head and neck squamous cell carcinoma. It is for patients whose cancer has returned or spread and who cannot tolerate p…
Phase 2 • Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Custom mRNA vaccine takes on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a personalized mRNA vaccine called RH125 in 36 people with advanced solid tumors who have no standard treatment options left. The vaccine is custom-made based on each patient's tumor mutations and is given alone or with a PD-1 blocker. The main goals …
Early phase 1 • Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center • Aim: Disease control
Last updated Jun 26, 2026 19:21 UTC